Two cases of atypical chronic myeloid leukaemia (CML) carrying the t(4;22)(q12;q11) translocation involving the breakpoint cluster region (BCR) and platelet-derived growth factor a receptor (PDGFRA) genes have been recently characterized. We report a third case of atypical CML with the same translocation but with a distinct breakpoint fusing BCR exon 1 with PDGFRA exon 13. The patient had a clinical presentation of CML with progressive transformation in B-cell acute lymphoblastic leukaemia. The involvement of PDGFRA led us to treat the patient with the small organic compound imatinib mesylate/STI571 (Glivec) that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and plateletderived growth factor receptors. The patient subsequently achieved a rapid clinical and molecular response clearly demonstrating, for the first time, that Glivec is active against PDGFRA in vivo. Therefore, our study expands the list of Glivec targets and has direct biological and also clinical implications. Oncogene (2003Oncogene ( ) 22, 5702-5706. doi:10.1038 Keywords: Chronic myeloid leukaemia; STI-571/ Glivec; PDGFRA Chronic myeloid leukaemia (CML) is defined by the presence of the t(9;22)(q34;q11) translocation generating the breakpoint cluster region-Abelson (BCR-ABL) fusion gene (for a review, see Thijsen et al., 1999) . This translocation yields a constitutively active tyrosine kinase, which is the main and probably the starting oncogenic event in CML by stimulating proliferation and inhibiting apoptosis (Thijsen et al., 1999) . The most important breakthrough in the treatment of CML is the description of a small organic compound, imatinib mesylate/STI571 (Glivec), that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and platelet-derived growth factor receptors (PDGFR) (Druker et al., 1996; Buchdunger et al., 2000; Druker, 2002) . Besides CML, this molecule has been successfully used in patients with gastrointestinal stromal tumours (GIST) with KIT overexpression (van Oosterom et al., 2001; Demetri et al., 2002) , and in some cases of chronic myeloproliferative diseases with overexpression of a fusion protein involving platelet-derived growth factor b receptor (PDGFRB) (Apperley et al., 2002; Magnusson et al., 2002) . Glivec has also proved to be effective in the treatment of dermatofibrosarcoma protuberans, which owes its pathogenesis to the PDGFRB activation through induced overexpression of its ligand (Maki et al., 2002; Rubin et al., 2002) . Interestingly, in a recent report, Heinrich et al. (2003) have demonstrated that in GIST, KIT and platelet-derived growth factor a receptor (PDGFRA), mutations appeared to be alternative and mutually exclusive oncogenic mechanisms. This strongly suggests that PDGFRA is an important oncogene in solid tumours.
Chronic myeloid leukaemia (CML) is defined by the presence of the t(9;22)(q34;q11) translocation generating the breakpoint cluster region-Abelson (BCR-ABL) fusion gene (for a review, see Thijsen et al., 1999) . This translocation yields a constitutively active tyrosine kinase, which is the main and probably the starting oncogenic event in CML by stimulating proliferation and inhibiting apoptosis (Thijsen et al., 1999) . The most important breakthrough in the treatment of CML is the description of a small organic compound, imatinib mesylate/STI571 (Glivec) , that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and platelet-derived growth factor receptors (PDGFR) (Druker et al., 1996; Buchdunger et al., 2000; Druker, 2002) . Besides CML, this molecule has been successfully used in patients with gastrointestinal stromal tumours (GIST) with KIT overexpression (van Oosterom et al., 2001; Demetri et al., 2002) , and in some cases of chronic myeloproliferative diseases with overexpression of a fusion protein involving platelet-derived growth factor b receptor (PDGFRB) (Apperley et al., 2002; Magnusson et al., 2002) . Glivec has also proved to be effective in the treatment of dermatofibrosarcoma protuberans, which owes its pathogenesis to the PDGFRB activation through induced overexpression of its ligand (Maki et al., 2002; Rubin et al., 2002) . Interestingly, in a recent report, Heinrich et al. (2003) have demonstrated that in GIST, KIT and platelet-derived growth factor a receptor (PDGFRA), mutations appeared to be alternative and mutually exclusive oncogenic mechanisms. This strongly suggests that PDGFRA is an important oncogene in solid tumours.
However, in leukaemia, the mechanism of PDGFRA activation seems to be related to chromosomal translocations as described by the recent report of two cases of CML-like syndromes with the t(4;22)(q12;q11) translocation, involving BCR and PDGFRA. The two patients had an unusual in-frame BCR-PDGFRA fusion mRNA with either BCR exon 7 or exon 12 fused to unexpected additional nucleotide sequences, fused in both cases to PDGFRA exon 12 . Here, we report on a third case occurring in a patient who underwent an acute phase (B-cell acute lymphoblastic leukaemia).
In January 2002, a 47-year-old man was referred to our institution for severe coronary insufficiency. At this time, blood examination revealed hyperleucocytosis (32.3 Â 10 9 /l) with 72% polymorphonuclear cells, 2% eosinophils, 0% basophils, 7% lymphocytes, 13% monocytes, 3% metamyelocytes, and 3% myelocytes. Haemoglobin and platelet counts were within normal ranges. Physical examination was normal. The diagnosis of chronic myeloproliferative disorder was suspected. However, because of the severity of the coronaropathy, haematological examinations were delayed. After 1 month, he developed suddenly night sweats, fever, fatigue, weight loss and bone pains, and for this reason was referred to our department on 4 February 2002. Physical examination revealed diffuse ecchymosis, multiple lymphadenopathies and hepatosplenomegaly. Blood tests showed hyperleucocytosis (139 Â 10 9 /l) with 27% polymorphonuclear cells, 4% eosinophils, 0% basophils, 3% lymphocytes, 5% monocytes, 12% metamyelocytes, 13% myelocytes and 36% blast cells. Haemoglobin was normal (139 g/l) whereas platelet count was slightly reduced (142 Â 10 9 /l). Bone marrow aspirate showed increased cellularity with 73% blast cells. Morphology, cytochemistry and immunophenotype analysis identified blast cells as pre-B cells. As a result of the previously documented leucocyte abnormalities, we evoked the diagnosis of Philadelphia (Ph1)-positive pre-B-cell acute lymphoblastic leukaemia. However, cytogenetic analysis revealed no Ph1 but a sole t(4;22)(q12;q11) translocation in 95% of the cells. Cerebrospinal fluid was normal. Chemotherapy was started and consisted in the administration of daunorubicin, cyclophosphamide, corticosteroids, L-asparaginase and intrathecal methotrexate according to the LALA 2002 French multicentric protocol. Clinical and haematological response were achieved 5 weeks later. Owing to the lack of both related and unrelated HLAmatched donor, he was planned to receive an intensification with high-dose cytarabine and mitoxantrone. However, just before intensification (8 April), blood examination showed hyperleucocytosis (25.1 Â 10 9 /l) with excess of polymorphonuclear cells, monocytosis, myelocytes and metamyelocytes, whereas no circulating or marrow blast cell was detected. At this time, cytogenetic analysis showed 100% cytogenetically abnormal cells. Nevertheless, intensification was performed. Interestingly, after a short period of chemotherapy-induced aplasia, blood examination revealed again hyperleucocytosis (34.2 Â 10 9 /l) with 47% polymorphonuclear cells, 2% eosinophils, 1% basophils, 5% lymphocytes, 19% monocytes, 18% metamyelocytes, 3% myelocytes and 5% promyelocytes. The t(4;22) was found in 87% of the marrow cells, whereas no blast excess could be detected. Chemotherapy consolidation was still continued consisting of methotrexate, asparaginase and corticosteroids, whereas central nervous system prophylaxis was completed. Despite treatment, leucocytosis increased between each cycle until July 2002. Blood examination revealed hyperleucocytosis (64.2 Â 10 9 /l) with 45% polymorphonuclear cells, 3% eosinophils, 0% basophils, 5% lymphocytes, 18% monocytes, 20% metamyelocytes, 4% myelocytes and 5% promyelocytes, whereas t(4;22) was found in 70% of the marrow cells. Based on molecular analysis which showed that BCR was fused to PDGFRA (see below), Glivec was started at the dose of 400 mg/day. Under therapy with Glivec alone, the patient achieved a complete haematological response within 6 weeks. At this time (September 2002), bone marrow aspirate was normal, whereas cytogenetic analysis detected t(4;22) in only 15% of the marrow cells. Glivec was maintained as single therapy until October 2002. Unfortunately, the patient developed signs of meningitis.
Blast cells with additional cytogenetic abnormalities [45,-Y,t(3;12)(p23;q14),del(9)(p21),t(4;22)(q12;q11), der(9)ins(9;?)(q12;?)] were detected in the cerebrospinal fluid and corresponded to an isolated relapse suggesting 'a clonal' selection phenomenon. The imatinib therapy Figure 1 (a) FISH analysis: fluorescence in situ hybridization (FISH) with Vysis BCR-ABL ES translocation probe at diagnosis. FISH was performed with the Vysis BCR-ABL ES translocation probe (Vysis, Downers Grove, IL, USA) according to the manufacturer's instructions. The BCR signal (green) was split in the m-BCR region. The 3 0 BCR part was translocated onto chromosome 4 (4q12). Chromosome 9 and ABL gene were not involved in the translocation: both ABL signals (red) are located in 9q34 of both chromosomes 9. (b) Test for candidate genes: Nested-PCR analysis of potential chimerical transcripts involved in t(4;22)(q12;q11). Three genes were suspected to be involved in the rearrangement with m-BCR because of their localization at 4q11-12 and their implication in haematological disorders. Different hybrid messengers were tested : BTL-BCR, BCR-KIT, BCR-BTL, BCR-PDGFRA. Only BCR-PDGFRA mRNA is detected. Total RNA was extracted following the Trizol method (Gibco-BRL, Cergy Pontoise, France), reverse transcribed and amplified using the kit 'One step RT-PCR' (Gibco-BRL). Gene database searches were performed through the National Centre of Biotechnology Information (NCBI, Bethesda, MD, USA) using the OMIM network service. Primer sets were designed to amplify these genes (sequences below). Two successive amplifications, RT-PCR and nested PCR (30 and 35 cycles), were performed. The annealing temperature was 58 and 621C, respectively.
Primers sequences: (Figure 1a) . In addition, the breakpoint was localised on chromosome 22 within the m-BCR region (Figure 1a) . RT-PCR analysis confirmed the lack of BCR-ABL transcripts (not shown).
Among the three candidate genes mapped in the 4q11-12 region, we selected KIT and PDGFRA as potential partners of BCR because of their tyrosine kinase receptor structure. A third gene BTL (Brxlike translocated in leukaemia), also called CHIC2, is located in the same region. As it has been described in chromosomal translocations in leukaemia, BTL/ CHIC2 was regarded as a potential candidate gene. In particular, BTL has been previously identified as the partner of ETV6/TEL in cases of acute myeloid leukaemia (Cools et al., 1999) . Primer sets were designed to amplify these potential transcripts. We found PDGFRA to be the partner of m-BCR in this translocation (Figure 1b) . After sequencing, the breakpoint was distinct from those described by Baxter et al.
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P Trempat et al (2002) and fused BCR exon 1 with PDGFRA exon 13. Sequence analysis revealed that exons were in frame (Table 1) . Of note, the reciprocal chimerical gene PDGFRA-BCR was not transcribed (not shown). We herein report the third example of the new t(4;22)(q12;q11) translocation fusing BCR and PDGFRA genes. Similar to some translocations involving tyrosine kinase genes, this new translocation involves BCR with the preservation of its exon 1, which is mandatory for the production of the coiled-coil oligomerization that mimics normal activation of the PDGFRA by its ligand (Table 1 ) (McWhirter et al., 1993; Thijsen et al., 1999) . CML is characterized by the presence of the BCR-ABL fusion gene that produces a hybrid protein with tyrosine kinase activity (Druker et al., 1996; Thijsen et al., 1999; Druker, 2002) . The recent description of STI 571/Glivec as a specific inhibitor of tyrosine kinase of the Abelson family has provided considerable hopes for patients with CML. This compound is able to block the Table 1 Structure of fusion mRNA. (a) Open reading frame of the chimeric BCR-PDGFRA transcript. BCR exon 1 (NM_004327) is in-frame with PDGFRA exon 13 (NM_006206). (b) Structure of BCR, BCR-PDFGFRA and PDGFRA mRNAs. Exon numbers are indicated between arrowheads above each diagram. OD, oligomerization domain; S/TK, serine/threonine kinase; Rho-GEF, Rho guanine-nucleotide exchange factor homology domain; RAC-GAP, Rac GTPase-activating protein domain; Ig-like, immunoglobulin-like domains; TM, transmembrane domain; TK1,TK2 tyrosine kinase 1 and 2 domains; KI, kinase insert domain. A specific nested PCR was necessary to sequence the breakpoint between BCR and PDGFRA; the two primers were:
The PCR products were applied to a 1.5% agarose gel and the DNA band was excised under UV light and purified by Gene Clean kit (Qbiogene, Illkirch, France). This DNA was used as template for PCR sequencing, using the kit ABI Prism Dye Terminator (Perkin-Elmer Applied Biosystem, Warrington, UK)
Glu Gly Ala Phe His Gly Asp Ala Gly Leu Gly Ser Gly Ala Phe Gly Val Arg Gly GGC GAG GGC GCC TTC CAT GGA GAC GCA GGT CGG GTC TTG GGG TCT GGA GCG TTT GGG
BCR exon1
PDGFRA exon13 (Druker et al., 1996; Buchdunger et al., 2000; Druker, 2002) . On the basis of the results recently reported in chronic myeloproliferative diseases (Apperley et al., 2002; Magnusson et al., 2002) with rearrangements of the PDGFRB, we decided to treat this patient with STI571/Glivec. This treatment proved to be effective against bone marrow and leukaemia cells but, the central nervous system relapse confirms that Glivec has a poor penetration into cerebrospinal fluid as reported by others (Petzer et al., 2002) .
The results of the present study expand the list of Glivec targets and have direct clinical implication. In addition to myeloproliferative diseases bearing ABL or PDGFRB rearrangements, this molecule is also effective in CML-like disorders with fusion genes involving PDGFRA as demonstrated in the present study. We suspect that Glivec will also be effective in GIST overexpressing mutated PDGFRA.
